GSK adds detailed clinical trial data to multi-sponsor request system
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system that includes studies from multiple organisations.
Bayer plans to acquire Norwegian pharmaceutical company Algeta
- Details
- Category: Bayer
The Bayer Group plans to further strengthen its oncology portfolio with the acquisition of Norwegian pharmaceutical company Algeta ASA, Oslo. "We have already successfully collaborated with Algeta to develop and commercialize the cancer drug Xofigo™. The planned acquisition would give us full control over Xofigo™. We are absolutely convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options," commented Bayer CEO Dr. Marijn Dekkers.
Bristol-Myers Squibb to sell its global diabetes business
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
Pfizer settles Viagra® patent litigation with Teva
- Details
- Category: Pfizer
Pfizer Inc. announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity).
Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) have announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate against Alzheimer's disease.
FDA Advisory Committee votes on investigational medicine metreleptin
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy (LD).
Multimillion pound investment in UK life sciences research and development
- Details
- Category: UCB
UCB has today announced the successful completion of a £3.29 million investment in new, cutting-edge robotic laboratory equipment and purpose-built technology at its UK immunology research centre of excellence. The investment centres on an automated antibody discovery platform, designed and built especially for UCB by Farnborough based robotic laboratory experts company Peak Analysis & Automation Ltd (PAA).
More Pharma News ...
- Pfizer expands clinical trial data access policy and launches data access portal
- Novartis Africa Day highlights company's efforts to expand access to healthcare
- Only 29% of people with diabetes report that their doctors ask them for input for their own treatment plans
- New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin
- Pfizer acquires Polocard, Poland's leading over-the-counter heart attack prevention brand
- Novartis Foundation launches new leprosy strategy at symposium on disease elimination
- GSK responds to FDA decision on Avandia (rosiglitazone)